Stock Analysis
ExpreS2ion Biotech Holding Reports Third Quarter 2023 Earnings
ExpreS2ion Biotech Holding (STO:EXPRS2) Third Quarter 2023 Results
Key Financial Results
- Net loss: kr21.8m (loss narrowed by 29% from 3Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
ExpreS2ion Biotech Holding Earnings Insights
Looking ahead, revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Sweden.
Performance of the Swedish Biotechs industry.
The company's shares are up 8.0% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 6 warning signs for ExpreS2ion Biotech Holding (4 shouldn't be ignored) you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if ExpreS2ion Biotech Holding might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:EXPRS2
ExpreS2ion Biotech Holding
Through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally.